Search Results
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
outcomes,3 with an average BMI of more than 39 kg/m2 across both treatment arms. This reflects a mean BMI of approximately 9-10 kg/m2 higher than any population studied to date in Phase 3 pivotal trials of a psoriasis biologic.4-9 An increase in BMI has been shown to reduce
More news about: Eli Lilly and Company
Feb 15, 2026, 08:00 ET GLP-1s Associated with Reduced Asthma Exacerbation in Patients Without Diabetes
MD.Researchers used data from the global collaborative network in TriNetX to conduct this cohort study of overweight (BMI 25.00 - 29.99 kg/m2), obese (BMI 30.00 - 40.00 kg/m2) and morbidly obese (BMI at least 40.00 kg/m2) non-diabetic patients with asthma. The study compared exacerbation rates over a three-year
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 11, 2026, 16:16 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
tablet and the subcutaneous formulation. This trial is a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2). All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants
More news about: Viking Therapeutics, Inc.
Feb 09, 2026, 09:00 ET BMI OrganBank Announces Head-to-Head Preclinical Data for OrganBank Kidney Platform
use.About BMI OrganBankBMI OrganBank is a medical technology company developing advanced organ preservation and assessment systems designed to address time, data, and confidence limitations in transplantation. By enabling physiologic preservation and real-time insights, BMI OrganBank aims
More news about: BMI OrganBank
Feb 03, 2026, 12:35 ET Allegheny Health Network Opens First Heart Clinic in Pennsylvania Focused on Addressing Critical Health Disparities Among South Asian Patient Population
and morbidity rates within this population are disproportionately higher as well.More specifically, these patients may appear thin and not meet BMI criteria for obesity but have higher rates of abdominal obesity which leads to a higher risk profile, said Dr. Indaram."We understand that a 'one-size-fits-all'
More news about: Allegheny Health Network
Feb 03, 2026, 10:22 ET Americas Mineral Infrastructure Draws Capital As Critical Materials Deficits Deepen
Fitch's BMI forecasts the global silver market deficit will persist throughout 2026 as industrial consumption eclipses mine supply for a fifth consecutive year[3].
More news about: Equity Insider
Jan 29, 2026, 15:43 ET America's Beverage Companies & U.S. Conference of Mayors Award Nine Cities $1,000,000 for the Healthy & Sustainable Communities Grant Program
designed to increase fiscal stability (e.g., 70% of households establishing an emergency health fund), reduce non-mortgage debt, improve or stabilize youth BMI percentiles, boost caregivers' confidence in sourcing and preparing healthy meals, and build a scalable model linking economic and health gains.Third
More news about: U.S. Conference of Mayors
Jan 29, 2026, 12:29 ET Strategic Mineral Stocks Gain Ground as Pentagon Pushes for Secure Defense Supply Chains
https://www.mining.com/global-scramble-for-critical-minerals-to-shape-markets-in-2026-bmi4.
More news about: USA News Group
Jan 29, 2026, 09:15 ET Global Silver Shortage Triggers Historic $100 Breakout and Major Resource Rotation
https://www.mining.com/silver-market-deficit-to-continue-throughout-2026-says-fitchs-bmi/
More news about: Equity Insider
Jan 28, 2026, 10:00 ET BMI Imaging's "The Digital Imaging Channel" Surpasses 600 Subscribers on YouTube
https://www.bmiimaging.com.About BMI Imaging SystemsFounded in 1958, BMI Imaging Systems helps organizations convert paper, microfilm, and microfiche into secure, searchable digital collections. BMI provides public, private, and CJIS-compliant hosting solutions,
More news about: BMI Imaging Systems, Inc.
Jan 27, 2026, 07:00 ET United Expects Biggest Summer Yet at Chicago O'Hare, Growing to Record 750 Flights Per Day
operated 4 times daily beginning May 7, 2026La Crosse, Wis. (LSE) operated 4 times daily beginning May 7, 2026Bloomington/Normal, Ill. (BMI) operated 4 times daily beginning May 7, 2026In late 2025, the airline also announced it would add flights to cities such as Santa Barbara,
More news about: United Airlines
Jan 23, 2026, 08:00 ET Alcresta Therapeutics Announces Publication of Real-World Evidence Showing Improvements in Growth for Children Ages 1 to 5 Years Old With Use of RELiZORB®
the secondary endpoints were change in BMI z-scores and percentiles from baseline to 12 months, and change in weight z-scores at 3, 6, and 9 months. Use of RELiZORB in this patient population demonstrated statistically significant improvements in mean weight and BMI z-scores from baseline to 12 months,
More news about: Alcresta Therapeutics
Jan 22, 2026, 11:05 ET PhaseV Demonstrates How AI-Driven Site Selection and Real-Time Analytics Reduce Recruitment Uncertainty and Accelerate IBD Clinical Trials
mathematically steered toward successful outcomes."PhaseV's ClinOps Optimizer improves clinical trial site selection by modeling covariates such as age, BMI, ethnicity, genomic markers, comorbidities, and treatment history. Using causal machine learning, the platform enables sponsors to estimate each site's
More news about: PhaseV
Jan 20, 2026, 10:15 ET The Sovereignty Trade: Washington's $2.5B Push to Secure Critical Minerals
https://www.mining.com/global-scramble-for-critical-minerals-to-shape-markets-in-2026-bmi/Logo:
More news about: USA News Group
Jan 15, 2026, 13:09 ET Kick off 2026 With the Top 25 Hottest FSA- and HSA-eligible Products from FSA Store® and HSA Store®
Aura – A smart scale that delivers key data right to your phone, including weight, body fat rate, body water, body age, body mass index (BMI), muscle mass, bone mass, body balance, basal metabolic rate (BMR), visceral fat, and protein.
More news about: Health-E Commerce
Jan 14, 2026, 15:46 ET BMI Imaging Introduces Bytreon™: A Verifiable Trusted System for Long-Term Records
evidence—clearly, consistently, and on demand.About BMI Imaging SystemsFounded in 1958, BMI Imaging Systems helps organizations convert paper, microfilm, and microfiche into secure, searchable digital collections. BMI offers public, private, and CJIS-compliant hosting solutions supported
More news about: BMI Imaging Systems, Inc.
Jan 13, 2026, 09:00 ET Cerapedics' PearlMatrix P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator, Now Approved for Expanded Indications for Use
market, as it demonstrated safety and improved time-to-fusion in both the overall and high risk-patient populations (i.e., patients with Type 2 diabetes, BMI ≥ 30 and/or nicotine users)."*Dr. Moss has provided advisory and speaking services to Cerapedics, Inc.; he has not been paid for any media
More news about: Cerapedics Inc.
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
VK2735 dosed weekly for 78 weeks. The VANQUISH-1 study has completed enrollment of approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is enrolling approximately
More news about: Viking Therapeutics, Inc.
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
PsA with data supporting a potential comprehensive treatment approach alongside an incretin therapy for patients who also have obesity (BMI ≥30 kg/m²) or overweight (BMI 27-29.9 kg/m²) with at least one weight-related conditionINDIANAPOLIS, Jan.
More news about: Eli Lilly and Company
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
VK2735 dosed weekly for 78 weeks. The VANQUISH-1 study has completed enrollment of approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is enrolling approximately
More news about: Viking Therapeutics, Inc.
Jan 05, 2026, 08:30 ET MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
tolerability, PK, and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese but otherwise healthy adults with a body mass index (BMI) of 30–45 kg/m². Nine subjects in each cohort were randomized in a 6:3 ratio, with each subject receiving either 4 weekly administrations of DA-1726
More news about: MetaVia Inc.
Dec 31, 2025, 08:07 ET The End of Shots? 5 Biotech Stocks Rethinking Diabetes
of 23% body weight when evaluating the treatment effect if all patients stayed on treatment, with 54% of patients with obesity at baseline reaching BMI below 30 kg/m2 at week 68. The trial included 3,417 adults with 87.4% of patients on steroids at baseline successfully tapering to prednisone 5 mg per
More news about: USA News Group
Dec 30, 2025, 08:00 ET OTO Fertility Launches World's First AI-Powered Platform & Wearable for Predictive Reproductive Insight
"Fertility Zone." The OTO Fertility Index™ is a more accurate indicator of pregnancy success than the current standard of care measurements including age, BMI, or AMH."Until now, there's been no accurate way to predict fertility outcomes based on what's actually happening in the body in real time," said
More news about: OTO Fertility
Dec 24, 2025, 21:05 ET Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
conducted at multiple centers in the United States. The study is expected to enroll approximately 120 subjects with obesity (BMI > 30) or overweight (BMI > 27) with comorbidities.The study will evaluate the efficacy, safety, and tolerability of CBL-514 in combination with Zepbound®
More news about: Caliway Biopharmaceuticals
Dec 22, 2025, 18:03 ET FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.1 People with diabetes were excluded.1
More news about: NOVO NORDISK INC.